CN105999296B - 一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法 - Google Patents
一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法 Download PDFInfo
- Publication number
- CN105999296B CN105999296B CN201610398081.4A CN201610398081A CN105999296B CN 105999296 B CN105999296 B CN 105999296B CN 201610398081 A CN201610398081 A CN 201610398081A CN 105999296 B CN105999296 B CN 105999296B
- Authority
- CN
- China
- Prior art keywords
- preparation
- fsinps
- silicon dioxide
- nano particle
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 23
- 230000008499 blood brain barrier function Effects 0.000 title claims abstract description 22
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 22
- 235000012239 silicon dioxide Nutrition 0.000 title claims abstract description 22
- 210000001218 blood-brain barrier Anatomy 0.000 title claims abstract description 13
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000002243 precursor Substances 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 8
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 238000003760 magnetic stirring Methods 0.000 claims description 5
- 238000005352 clarification Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 14
- 230000005540 biological transmission Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000003139 buffering effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 238000009938 salting Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及不同粒径跨血脑屏障膜荧光二氧化硅的制备方法,包括荧光3‑氨丙基三乙氧基硅烷前体的制备,荧光二氧化硅纳米颗粒FSiNPs的制备,FSiNPs‑PEG2000‑Mal的制备,FSiNPs‑PEG2000‑CDX的制备。该方法控制反应条件制备不同尺寸的荧光二氧化硅纳米颗粒,并在其表面选择性连接跨血脑屏障膜靶向分子。该荧光纳米颗粒具有结构稳定、生物相容性好、荧光信号强等特点。所得的产物能满足科研的需求。本发明中的制备方法工艺简单,可操作性强,能进一步满足生产和应用。
Description
技术领域
本发明具体涉及一种以二氧化硅为介质,同时连接荧光分子和血脑屏障靶向分子的制备技术。本发明属于纳米生物医药材料领域。
背景技术
根据世界卫生组织(WHO)在2008年的报道,在全球范围内,脑肿瘤的发病率大约为3.5/100,000。在全身肿瘤的发病率中,其发病率仅次于胃、子宫、乳腺及食管癌的发病率。此外,脑肿瘤病人的中位生存期非常短,仅为16个月,在不治疗的情况下,只有3 %-10 %的病人能活过5年。目前,由于脑肿瘤,尤其是脑胶质瘤呈浸润性生长,与周围正常脑组织边界不清, 使得手术完全切除十分困难,从而导致较高的复发率。而化疗不仅能杀灭尚处于初期的脑肿瘤细胞,还能对术后残留的脑肿瘤细胞起到杀伤作用,从而防止脑肿瘤的复发。但是,在脑肿瘤化疗方面,最为突出的问题就是由于血脑屏障(BBB,blood-brain barrier)的存在,抗癌药物自身不能进入脑内,从而对脑肿瘤治疗起到阻碍作用。
之所以BBB对化疗药物起着阻碍效果,这还得归结于其自身的结构特点。BBB主要是由脑微血管内皮细胞(ECs)、内皮细胞间紧密连接(TJs)、基膜、周细胞和星形胶质细胞组成。由于TJs的存在,血管内皮细胞对血液中携带的分子的通透性十分低。有研究发现BBB上的膜孔径大小约为0.4 nm,比非神经内皮细胞的孔径(6-7 nm)要小的多。此外,TJs还使得BBB有很高的电阻值(1000-2000 Ω / cm2),从而能够阻止极性以及带电荷的物质进入脑内。
如何穿越BBB并对脑肿瘤进行给药治疗,困扰着广大的科研工作者。随着纳米技术的出现,利用纳米材料进行脑肿瘤靶向递药取得了极大的发展。研究人员通常利用纳米材料为递药载体,通过在载体表面修饰上靶向分子(小分子、寡聚核苷酸、多肽、抗体等),利用BBB表面存在的受体,使得药物载体能够在受体介导内吞机制的帮助下主动穿透BBB屏障膜,从而进入脑肿瘤区域并释药,最终达到治愈脑肿瘤的目的。
尽管在脑肿瘤靶向递药上取得了一些成果,但目前脑肿瘤靶向递药仍然存在靶向性低的问题,具体表现为递药载体穿越BBB的能力较低,从而对治疗效果造成较大的影响。针对这一问题,我们认为药物载体的粒径大小很可能是影响靶向效果的重要因素。
发明内容
为克服现有技术的不足,本发明提供一种不同粒径跨血脑屏障膜荧光二氧化硅的制备方法。为实现这样的目的,在本发明的技术方案中,我们首先用3-氨丙基三乙氧基硅烷(APTES)对得到的荧光二氧化硅纳米颗粒(FSiNPs)进行表面修饰,使其表面修饰上氨基基团,为后续聚乙二醇(PEG)的嫁接提供了可能。接着我们利用NHS( N-羟基琥珀酰亚胺)和氨基的特异性反应,将NHS-PEG2000-Mal修饰至FSiNPs表面。为了构建有靶分子的FSiNPs,通过Mal(马来酰亚胺)基团和巯基(-SH)的特异性反应,CDX(乙酰胆碱受体介导脑靶向多肽)被修饰至SiNPs-PEG2000上。
一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法,其特征在于,包括如下步骤:
(1)荧光3-氨丙基三乙氧基硅烷前体的制备
取2.0 mg 含羧基的荧光分子,分散在1.0 mL乙醇中,超声一小段时间,待溶液澄清后,在磁力搅拌器的作用下,加入80μL 3-氨丙基三乙氧基硅烷(APTES),避光反应24小时,制备得到荧光APTES前体;
(2)荧光二氧化硅纳米颗粒FSiNPs的制备
依次将0.5 mL TEOS和0.1 mL荧光APTES前体溶解在乙醇/水的混合溶剂中,乙醇:水=0.5:1-2:1,然后与0.1-1.0 mL 25% 浓氨水混合,搅拌反应24小时,随后依次用乙醇和水洗涤3遍,最后4摄氏度保存二甲基甲酰胺(DMF)中,制备得到FSiNPs;
(3)FSiNPs-PEG2000-Mal的制备
将1.6 微升三乙胺加入到上述FSiNPs的DMF溶液中,搅拌均匀,加入20 mg NHS-PEG2000-Mal,室温下反应2小时;分别用DMF以及水离心洗涤,保存在1.0 mL 10 mM PBS(磷酸缓冲盐溶液,pH 7.4)中;
(4)FSiNPs-PEG2000-CDX的制备
称取1.0 mg SH-CDX,将其加入到上述PBS中,过夜搅拌反应;反应液用PBS、水离心洗涤,最后4摄氏度保存在水相中,1.0 mL。
所述的含羧基的荧光分子为6-羧基荧光素、5-羧基荧光素、荧光素cy3、荧光素cy5.5、6-羧基四甲基罗丹明的一种。
该方法控制反应条件制备不同尺寸的荧光二氧化硅纳米颗粒,并在其表面选择性连接跨血脑屏障膜靶向分子。该荧光纳米颗粒具有结构稳定、生物相容性好、荧光信号强等特点。所得的产物能满足科研的需求。
本发明的优点在于:
(1)本发明以荧光二氧化硅为介质,通过偶联的方法将血脑屏障膜靶向分子嫁接其上,所用原料生物安全性高。
(2)本发明制备的荧光纳米颗粒具有良好的物理化学稳定性、发光性能和血脑屏障膜靶向性能。
(3)本发明中的制备方法工艺简单,可操作性强,能进一步满足生产和应用。
附图说明
图1为实施例1所制备的30 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
图2为实施例2所制备的50 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
图3为实施例3所制备的100 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
图4为实施例4所制备的200 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
具体实施方式
以下通过具体的实施例对本发明的技术方案作进一步描述。以下的实施例是对本发明的进一步说明,而不限制本发明的范围。
实施例1:
1. 荧光APTES前体的制备
取2.0 mg 6-羧基荧光素,分散在1.0 mL乙醇中,超声一小段时间,待溶液澄清后,在磁力搅拌器的作用下,加入80 微升 APTES,避光反应24小时,制备得到荧光APTES前体。
2. FSiNPs的制备
依次将0.5 mL TEOS和0.1 mL荧光APTES前体溶解在乙醇/水的混合溶剂中(乙醇:水=0.5:1),然后与0.1 mL 25% 浓氨水混合,搅拌反应24小时。随后依次用乙醇和水洗涤3遍,最后4摄氏度保存DMF中,制备得到FSiNPs。
3. FSiNPs-PEG2000-Mal的制备
将1.6 微升三乙胺加入到上述FSiNPs的DMF溶液中,搅拌均匀,加入20 mg NHS-PEG2000-Mal,室温下反应2小时。分别用DMF以及水离心洗涤,保存在1.0 mL 10 mM PBS (磷酸缓冲盐溶液,pH 7.4)中。
4. FSiNPs-PEG2000-CDX的制备
称取1.0 mg SH-CDX,将其加入到上述PBS中,过夜搅拌反应。反应液用PBS、水离心洗涤,最后4摄氏度保存在水相中(1.0 mL)。
图1为所制备的粒径为30 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
实施例2:
1. 荧光APTES前体的制备
取2.0 mg荧光素cy3,分散在1.0 mL乙醇中,超声一小段时间,待溶液澄清后,在磁力搅拌器的作用下,加入80 微升 APTES,避光反应24小时,制备得到荧光APTES前体。
2. FSiNPs的制备
依次将0.5 mL TEOS和0.1 mL荧光APTES前体溶解在乙醇/水的混合溶剂中(乙醇:水=1:1),然后与0.2 mL 25% 浓氨水混合,搅拌反应24小时。随后依次用乙醇和水洗涤3遍,最后4摄氏度保存DMF中,制备得到FSiNPs。
3. FSiNPs-PEG2000-Mal的制备
将1.6 微升三乙胺加入到上述FSiNPs的DMF溶液中,搅拌均匀,加入20 mg NHS-PEG2000-Mal,室温下反应2小时。分别用DMF以及水离心洗涤,保存在1.0 mL 10 mM PBS (磷酸缓冲盐溶液,pH 7.4)中。
4. FSiNPs-PEG2000-CDX的制备
称取1.0 mg SH-CDX,将其加入到上述PBS中,过夜搅拌反应。反应液用PBS、水离心洗涤,最后4摄氏度保存在水相中(1.0 mL)。
图2为所制备的粒径为50 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
实施例3:
1. 荧光APTES前体的制备
取2.0 mg荧光素cy5.5,分散在1.0 mL乙醇中,超声一小段时间,待溶液澄清后,在磁力搅拌器的作用下,加入80 微升 APTES,避光反应24小时,制备得到荧光APTES前体。
2. FSiNPs的制备
依次将0.5 mL TEOS和0.1 mL荧光APTES前体溶解在乙醇/水的混合溶剂中(乙醇:水=1.5:1),然后与0.5 mL 25% 浓氨水混合,搅拌反应24小时。随后依次用乙醇和水洗涤3遍,最后4摄氏度保存DMF中,制备得到FSiNPs。
3. FSiNPs-PEG2000-Mal的制备
将1.6 微升三乙胺加入到上述FSiNPs的DMF溶液中,搅拌均匀,加入20 mg NHS-PEG2000-Mal,室温下反应2小时。分别用DMF以及水离心洗涤,保存在1.0 mL 10 mM PBS (磷酸缓冲盐溶液,pH 7.4)中。
4. FSiNPs-PEG2000-CDX的制备
称取1.0 mg SH-CDX,将其加入到上述PBS中,过夜搅拌反应。反应液用PBS、水离心洗涤,最后4摄氏度保存在水相中(1.0 mL)。
图3为所制备的粒径为100 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
实施例4:
1. 荧光APTES前体的制备
取2.0 mg6-羧基四甲基罗丹明,分散在1.0 mL乙醇中,超声一小段时间,待溶液澄清后,在磁力搅拌器的作用下,加入80 微升 APTES,避光反应24小时,制备得到荧光APTES前体。
2. FSiNPs的制备
依次将0.5 mL TEOS和0.1 mL荧光APTES前体溶解在乙醇/水的混合溶剂中(乙醇:水=2:1),然后与1 mL 25% 浓氨水混合,搅拌反应24小时。随后依次用乙醇和水洗涤3遍,最后4摄氏度保存DMF中,制备得到FSiNPs。
3. FSiNPs-PEG2000-Mal的制备
将1.6 微升三乙胺加入到上述FSiNPs的DMF溶液中,搅拌均匀,加入20 mg NHS-PEG2000-Mal,室温下反应2小时。分别用DMF以及水离心洗涤,保存在1.0 mL 10 mM PBS (磷酸缓冲盐溶液,pH 7.4)中。
4. FSiNPs-PEG2000-CDX的制备
称取1.0 mg SH-CDX,将其加入到上述PBS中,过夜搅拌反应。反应液用PBS、水离心洗涤,最后4摄氏度保存在水相中(1.0 mL)。
图4为所制备的粒径为200 nm荧光二氧化硅纳米颗粒的透射电子显微镜图。
Claims (2)
1.一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法,其特征在于,包括如下步骤:
(1)荧光3-氨丙基三乙氧基硅烷前体的制备
取2.0 mg 含羧基的荧光分子,分散在1.0 mL乙醇中,超声一小段时间,待溶液澄清后,在磁力搅拌器的作用下,加入80μL 3-氨丙基三乙氧基硅烷(APTES),避光反应24小时,制备得到荧光APTES前体;
(2)荧光二氧化硅纳米颗粒FSiNPs的制备
依次将0.5 mL TEOS和0.1 mL荧光APTES前体溶解在乙醇/水的混合溶剂中,乙醇:水=0.5:1-2:1,然后与0.1-1.0 mL 25% 浓氨水混合,搅拌反应24小时,随后依次用乙醇和水洗涤3遍,最后4摄氏度保存在 二甲基甲酰胺(DMF)中,制备得到FSiNPs;
(3)FSiNPs-PEG2000-Mal的制备
将1.6 µL三乙胺加入到上述FSiNPs的DMF溶液中,搅拌均匀,加入20 mg NHS-PEG2000-Mal,室温下反应2小时;分别用DMF以及水离心洗涤,保存在1.0 mL pH 7.4的10 mM PBS中;
(4)FSiNPs-PEG2000-CDX的制备
称取1.0 mg 巯基化乙酰胆碱受体介导脑靶向多肽SH-CDX,将其加入到上述PBS中,过夜搅拌反应;反应液用PBS、水离心洗涤,最后4摄氏度保存在水相中,1.0 mL。
2.根据权利要求1所述一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法,其特征在于,所述的含羧基的荧光分子为6-羧基荧光素、5-羧基荧光素、荧光素cy3、荧光素cy5.5、6-羧基四甲基罗丹明的一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610398081.4A CN105999296B (zh) | 2016-06-07 | 2016-06-07 | 一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610398081.4A CN105999296B (zh) | 2016-06-07 | 2016-06-07 | 一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105999296A CN105999296A (zh) | 2016-10-12 |
CN105999296B true CN105999296B (zh) | 2019-02-05 |
Family
ID=57090330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610398081.4A Active CN105999296B (zh) | 2016-06-07 | 2016-06-07 | 一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105999296B (zh) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1456678A (zh) * | 2002-05-09 | 2003-11-19 | 中南大学 | 一种生物标志物——荧光硅纳米颗粒的制备方法 |
US20040101822A1 (en) * | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
US8507556B2 (en) * | 2007-09-22 | 2013-08-13 | Boise State University | Fluorescent particles comprising nanoscale ZnO layer and exhibiting cell-specific toxicity |
CN102212116B (zh) * | 2010-04-02 | 2013-07-10 | 复旦大学 | 一种乙酰胆碱受体介导脑靶向多肽及其应用 |
CN102234507A (zh) * | 2010-05-05 | 2011-11-09 | 张永昶 | 荧光二氧化硅纳米球的制备 |
CN101935365B (zh) * | 2010-08-25 | 2012-03-21 | 华东理工大学 | 一种脑靶向基头修饰性环糊精衍生物的合成方法 |
CN102350281A (zh) * | 2011-06-24 | 2012-02-15 | 东北师范大学 | 基于荧光介孔二氧化硅蛋黄-蛋壳纳米胶囊的制备方法 |
CN103566380A (zh) * | 2012-07-24 | 2014-02-12 | 上海纳米技术及应用国家工程研究中心有限公司 | 基于上转换材料钆螯合物双功能造影剂的制备方法 |
CN105018075B (zh) * | 2015-07-21 | 2017-08-25 | 湖北工业大学 | 一类荧光纳米球及其制备方法 |
-
2016
- 2016-06-07 CN CN201610398081.4A patent/CN105999296B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105999296A (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Feng et al. | Charge-convertible carbon dots for imaging-guided drug delivery with enhanced in vivo cancer therapeutic efficiency | |
Shen et al. | Biomedical applications of graphene | |
Yan et al. | Micro‐and Nanotechnologies for Intracellular Delivery | |
Lu et al. | Radiopaque tantalum oxide coated persistent luminescent nanoparticles as multimodal probes for in vivo near-infrared luminescence and computed tomography bioimaging | |
Fisichella et al. | Uptake of functionalized mesoporous silica nanoparticles by human cancer cells | |
CN109157662B (zh) | 一种人血清白蛋白-阿霉素交联物纳米颗粒及其应用 | |
CN104667289B (zh) | 一种抗肿瘤药物载体及其使用方法 | |
Wang et al. | Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy | |
Yang et al. | Magainin II modified polydiacetylene micelles for cancer therapy | |
BR112016015810B1 (pt) | Nanopartículas magnéticas funcionalizadas com catecol, produção e uso das mesmas | |
CN105001426B (zh) | 一种具有肿瘤靶向性的聚氨基酸接枝共聚物及其制备方法 | |
Yu et al. | Establishment of facile nanomedicine construction methodology to comprehensively overcome hurdles across tumor‐specific nano‐delivery | |
Liu et al. | Construction of fluorescein isothiocyanate-labeled MSNs/PEG/lycorine/antibody as drug carrier for targeting prostate cancer cells | |
CN110368501A (zh) | 一种rgd肽修饰的硼载药体系及其制备和应用 | |
Chen et al. | Noninvasive near-infrared light triggers the remote activation of thermo-responsive TRPV1 channels in neurons based on biodegradable/photothermal polymer micelles | |
CN105999296B (zh) | 一种不同粒径跨血脑屏障膜荧光二氧化硅纳米颗粒的制备方法 | |
CN110393807B (zh) | 一种二氧化硅纳米基因递送系统及其制备方法和应用 | |
CN104817688B (zh) | 一种表面电荷可转变的纳米凝胶及其制备方法以及一种表面电荷可转变的纳米凝胶载药颗粒 | |
CN105168230B (zh) | 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法 | |
Ku et al. | pH-Responsive globular poly (ethylene glycol) for photodynamic tumor therapy | |
Chen et al. | Theranostic nanosystem mediating cascade catalytic reactions for effective immunotherapy of highly immunosuppressive and poorly penetrable pancreatic tumor | |
CN103320471B (zh) | 一种非病毒基因载体及其制备方法 | |
CN114209850B (zh) | 一种负载阿霉素靶向碳点的制备及应用 | |
WO2019132830A2 (en) | Ultrasound susceptible magnetic directed nano drug carrier system | |
KR20180107745A (ko) | 기체 발포형 마이셀 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230921 Address after: 201306 C Building, 888 Huanhu West Second Road, Pudong New Area, Shanghai Patentee after: Shanghai Helan Nanotechnology Co.,Ltd. Address before: 200241 No. 28 East Jiangchuan Road, Shanghai, Minhang District Patentee before: SHANGHAI NATIONAL ENGINEERING RESEARCH CENTER FOR NANOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |